Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?

2020 ◽  
Vol 26 (10) ◽  
pp. 2018-2020
Author(s):  
Andrea Villasco ◽  
Marta D’Alonzo
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Extended Endocrine Therapy

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients

Breast Cancer ◽  
2012 ◽  
Vol 21 (5) ◽  
pp. 557-562 ◽  
Author(s):  
Daisuke Shimizu ◽  
Takashi Ishikawa ◽  
Mikiko Tanabe ◽  
Takeshi Sasaki ◽  
Yasushi Ichikawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Hormone Receptor Positive ◽  
Goserelin Acetate

A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 517-517
Author(s):  
hee Jeong Kim ◽  
Woo Chul Noh ◽  
Eun Sook Lee ◽  
Leesu Kim ◽  
Yongsik Jung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
Neoadjuvant Endocrine Therapy ◽  
Premenopausal Breast Cancer ◽  
Ki 67 ◽  
Initial Biopsy

517 Background: Neoadjuvant endocrine therapy has shown efficacy in hormone-responsive postmenopausal breast cancer patients. We aimed to assess the efficacy and safety of cytotoxic chemotherapy versus endocrine therapy for hormone-responsive lymph node-positive premenopausal breast cancer patients in a neoadjuvant setting. (NCT01622361). Methods: In this phase 3, randomized, double blind, parallel group, multicenter study, we enrolled premenopausal women with estrogen receptor (ER)-positive, HER2-negative, and lymph node-positive premenopausal breast cancer patients. Patients were randomized to either 24 weeks of neoadjuvant chemotherapy with adriamycin plus cyclophosphamide (AC) followed by taxane (T) or neoadjuvant endocrine therapy with zoladex and tamoxifen. Results: 187 patients were randomly assigned to chemotherapy (n=95) or endocrine therapy (n=92), and 174 patients completed the 24 week neoadjuvant treatment period (n=87, both). More patients in the chemotherapy group had a complete or partial response than did those in endocrine therapy arm on both caliper (chemotherapy 83.9% vs endocrine therapy 71.3%, OR 0.476 95% CI 0.228 to 0.994) and MRI (chemotherapy 83.7% vs endocrine therapy 52.9%, OR 0.219, 95% CI 0.107 to 0.447). Three patient on chemotherapy group (3.4%) and 1 patients (1.15%) on endocrine treatment group showed complete pathologic response. In the patients who had breast cancer with low Ki 67 expression (<20%) on initial biopsy, clinical response on caliper were shown similar on both treatment group (HR 0.958, 95%CI 0.296 to 3.101). Five patients who had no tumor on the breast or lymph node after 24 week neoadjuvant endocrine therapy had higher ER score (all allred score >6), all low grade (1or 2) low Ki 67(≤20%) expression (4/5 patients) on initial biopsy specimen. Conclusions: In premenopausal breast cancer patients, 24 weeks neoadjuvant chemotherapy showed better clinical response than endocrine therapy. Low Ki 67 expression could be a parameter of the endocrine treatment. Clinical trial information: NCT01622361.

scholarly journals Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico

The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. S19-S20
Author(s):  
C. Villarreal-Garza ◽  
F. Mesa-Chavez ◽  
C. De la Garza-Ramos ◽  
A.S. Ferrigno ◽  
K. Villanueva-Tamez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Prescribing Practices ◽  
Premenopausal Breast Cancer

scholarly journals LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

2021 ◽  
Vol 32 ◽  
pp. S21
Author(s):  
A. Johansson ◽  
H. Dar ◽  
L. Van ‘T Veer ◽  
G. Perez-Tenorio ◽  
A. Nordenskjöld ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer

scholarly journals IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Stacey E. P. Joosten ◽  
Marius Wellenstein ◽  
Rutger Koornstra ◽  
Annelot van Rossum ◽  
Joyce Sanders ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Postmenopausal Breast Cancer ◽  
Premenopausal Women ◽  
Blood Levels ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Estradiol Levels

AbstractWindow studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response. Immunohistochemistry (IHC)-based Ki67 on tissue from neo-adjuvant trials was previously reported to be predictive for long-term response to endocrine therapy for breast cancer in postmenopausal women, but none of these trials enrolled premenopausal women. Nonetheless, the marker is being used on this subpopulation. We compared pathologist assessed IHC-based Ki67 in samples from pre- and postmenopausal women in a neo-adjuvant, endocrine therapy focused trial (NCT00738777), randomized between tamoxifen, anastrozole, or fulvestrant. These results were compared with (1) IHC-based Ki67 scoring by AI, (2) mitotic figures, (3) mRNA-based Ki67, (4) five independent gene expression signatures capturing proliferation, and (5) blood levels for tamoxifen and its metabolites as well as estradiol. Upon tamoxifen, IHC-based Ki67 levels were decreased in both pre- and postmenopausal breast cancer patients, which was confirmed using mRNA-based cell proliferation markers. The magnitude of decrease of Ki67 IHC was smaller in pre- versus postmenopausal women. We found a direct relationship between post-treatment estradiol levels and the magnitude of the Ki67 decrease in tumors. These data suggest IHC-based Ki67 may be an appropriate biomarker for tamoxifen response in premenopausal breast cancer patients, but anti-proliferative effect size depends on estradiol levels.

Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 512-512 ◽  
Author(s):  
G. Pfeiler ◽  
R. Königsberg ◽  
C. F. Singer ◽  
M. Seifert ◽  
P. C. Dubsky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Body Mass ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document